Actavis Group, the international generic pharmaceuticals company, today announced the launch of Fluvastatin SR in the UK and the Netherlands. Actavis was first to market in both countries.
Fluvastatin SR extended release tablets from Actavis are the generic equivalent of Novartis’ Luvinsta® SR / Lescol® XL and are available in 80mg tablets in both markets. Fluvastatin SR is used to treat high cholesterol levels in the blood.
Fluvastatin SR tablets are manufactured by Actavis Malta and developed by Actavis’ R&D in Iceland.
This launch was possible after Actavis won a court case in January 2009 in the UK, whereby Novartis’ formulation patent for Fluvastatin SR, which prevented launch of the product until 2017, was revoked. The formulation patent has also been revoked in the Netherlands. Read more…
Actavis Group and Japan’s ASKA Pharmaceutical formally signed contracts recently establishing a new joint company called Actavis ASKA K.K. The new business will be headquartered in Tokyo.
The joint company intends to enter the Japanese generic pharmaceutical market right away in April 2009. ASKA will hold a 55 percent stake in the venture and Actavis will hold 45 percent.
“We are convinced this is the best way to enter the Japanese market,” says Actavis CEO Sigurdur Oli Olafsson. “We bring the power of a global generic pharmaceutical company to the table, while ASKA is an experienced local partner. We are very much looking forward to a long and successful partnership. The government’s policy to increase the share of generics during the next few years is key to our decision to enter at this time.”
Contributing to society by developing and providing innovative pharmaceutical products, ASKA Pharmaceutical is a research and development (R&D) orientated company located in Tokyo. ASKA concentrates its management resources on specific therapeutic areas.
Actavis is one of the world’s biggest generic pharmaceutical companies. Established in 1956, the group has more than 10,000 employees operating in over 40 countries around the globe. Actavis’ headquarters are in Iceland.
Actavis Group and ASKA Pharmaceutical formally signed the agreement establishing the new joint company: Actavis ASKA K.K following the signature of a preliminary agreement last November.
For further details, visit www.actavis.com
Recent Comments